Welcome to Chicago – and Happy Anniversary!

Over the course of our 60-year history, SWOG helped gain FDA approval for 14 new cancer drugs and changed the standard of care in oncology well over 100 times. This work, formally assessed by our own statisticians, has extended the lives of thousands of people by thousands of years. Our theme for this meeting and celebration is: Let’s Make More Time. In my plenary remarks on Friday, I’ll tell you just how much time we’ve given people touched by cancer. The number is stunning.

At our semi-annual meetings, we come together to learn and to plan. Here in Chicago, we also get to commemorate – our past, future, evolution, and impact. Among our many anniversary events, you can join SWOG digital engagement leader Dr. Don Dizon at a special coffee kick-off on Friday morning, then help me toast our success with a cake and cocktails reception Friday night.

We will hear great speakers at Plenary I and II. We’ll give away SWOG souvenirs. Best of all, we’re mounting a special interactive anniversary exhibit, which you can visit near the central registration desk. The exhibit showcases key SWOG initiatives and milestones, and includes a timeline of our biggest clinical trials. You can hear member stories – and learn how you can chronicle your own through StoryCorps, the national oral history project that’s recording a dozen cancer research stories from SWOG members right here in Chicago. Be sure to take a selfie and post it to Twitter or Facebook, and help us write a new chapter in SWOG history on our story wall.

Since 1956, we’ve enrolled more than 200,000 patients onto our trials. This year, the number has additional significance. To mark our anniversary, The Hope Foundation is issuing a fundraising challenge to support SWOG’s future. If together we give $100,000 to Hope in 2016, the foundation will match it dollar for dollar, so we can actually raise $200,000 – one dollar for every courageous and committed trial participant. All money raised will support Hope’s programs for young investigators – which ensures the brightest future for our group.

Please get ready for an historic meeting. Cheers!

Sincerely,

Charles D. Blanke, MD
Chair, SWOG
Plenary Sessions ........................................... 4, 13, & 14
The Hope Foundation ...................................... 5
Group Meeting Supporters ................................. 7 & 49
Hyatt Regency Travel
and Hotel Information and Hotel Maps .................. 10 & 11
Schedule of Events ........................................ 12-15
Administrative Committees ............................... 16
Committee Information:
Adolescent and Young Adult (AYA) Committee ....... 14
Barlogie-Salmon Myeloma Committee ............... 14, 15 & 19
Breast Committee ........................................ 15 & 20-21
Board of Governors ....................................... 15
Bone Marrow & Stem Cell Transplantation Committee 13
Cancer Control and Prevention Committees ........... 22
Cancer Care Delivery Committee ....................... 12 & 23
Cancer Survivorship Committee ......................... 13 & 24
Prevention and Epidemiology Committee .......... 14 & 25
Symptom Control and Quality of Life Committee ... 13 & 26-27
Digital Engagement Committee ......................... 13
Early Therapeutics and Rare Cancers Committee ...... 13 & 28-29
Gastrointestinal Committee ............................. 13, 15 & 30-31
Genitourinary Committee ................................ 14, 15 & 32-33
Imaging Committee ....................................... 14
Leukemia Committee ..................................... 15 & 34-35
Lung Committee .......................................... 13, 15 & 36-38
Lymphoma Committee .................................. 13, 15 & 39
Melanoma Committee ................................... 14 & 40
Patient Advocate Committee ........................... 12
Pharmaceutical Sciences Committee .................. 15
Radiation Oncology Committee ......................... 15
Surgery Committee ........................................ 14 & 17
SWOG Publications ...................................... 41-48
Special Symposia and Workshops ...................... 17-18
Jeri and Noboru Oishi Symposium .................... 12 & 17
Oncology Research Professionals (ORP) Open Forum.. 13 & 18
Site Operations ............................................ 12
Future Group Meeting Dates ............................ 16
CME Credit Information .................................. 7 & 8
Plenary Part 1
The fall meeting’s Translational Medicine Plenary will take place Thursday, September 15, 3:00-4:30 p.m. in Regency A-C. Speakers and topics will include the following:

Welcome and Introduction

Lee M. Ellis, M.D.
SWOG Vice Chair for Translational Medicine
University of Texas M. D. Anderson Cancer Center

The Application of Integrative Sequencing for Precision Oncology

Arul Chinnaiyan, M.D., Ph.D.
S.P. Hicks Endowed Professor of Pathology and Urology
University of Michigan

Ethical Dilemmas in Genomic Medicine

Carol Weil, J.D.
Program Director, Ethical and Regulatory Affairs
Cancer Diagnosis Program
National Cancer Institute

Innovations and Progress from Our Collaborative ITSC Program

Edison Liu, M.D.
President and CEO
The Jackson Laboratory

David Tuveson, M.D., Ph.D.
Deputy Director, Cold Spring Harbor Cancer Director, Cancer Therapeutics Initiative Cold Spring Harbor Laboratory

Plenary Part 2
The fall meeting’s General Plenary will take place Friday, September 16, 12:00-2:00 p.m. in Regency A-C.

Welcome and Introduction

Charles D. Blanke, M.D.
SWOG Chair
Oregon Health & Science University

Where We’ve Been: Changing Lives

Andrea Denicoff, MS, RN
Head, National Clinical Trials Network Clinical Trials Operations
Scientific Liaison, Patient Reported Outcomes
National Cancer Institute

Where We Are: NCI Informed Consent Update and National Clinical Trials Network Town Hall

Jeff Abrams, M.D.
Acting Director, Clinical Research
Associate Director, Cancer Therapy Evaluation Program
National Cancer Institute

Sheila Prindiville, M.D., M.P.H.
Director, Coordinating Center for Clinical Trials
National Cancer Institute

Where We’re Going: A New Era of Survivorship Research

Patricia A. Ganz, M.D.
Distinguished Professor, Health Policy & Management and Medicine
UCLA Schools of Public Health & Medicine Jonsson Comprehensive Cancer Center

Why We Matter: Making More Time for People With Cancer

Craig Blanford
SWOG Cancer Survivor
University of Texas Health Science Center at San Antonio
Invest in Our Future

As SWOG turns 60, we’re supporting its future leaders through the Young Investigators Training Course, Coltman Fellowship Program, and coming soon: SWOG/NCTN Leadership Academy.

Learn more at thehopefoundation.org

Connect with us
@SupportingSWOG
/SupportingSWOG

Please visit us near meeting registration and help us reach our goal of $100,000.00.

Kanwal Raghav, MD, of the MD Anderson Cancer Center, has been the recipient of a SWOG Young Investigator Award.
You are invited to join the discussion!

**S1403 Update Meeting**

**S1403**: A Randomized Phase II/III Trial of Afatinib Plus Cetuximab versus Afatinib Alone In Treatment-Naïve Patients with Advanced, EGFR Mutation Positive Non-Small Lung Cancer (NSCLC)

Friday, September 16 | 9:30-10:30 am | Gold Coast

**Participating site Investigators and staff are encouraged to attend.**

Hear a panel that includes members of the study team and a patient advocate. Get updates on the study accrual, discuss barriers and strategies, hear how you can use advocates to assist with accrual, get responses to the frequently asked questions, and more!
Procedures for CME Credit

We’ve gone paperless! SWOG no longer requires members to submit paper forms to obtain CME credits. Getting your credits online is easy:

- Visit: http://swog.org/Members/CMECertification.asp
- Complete the evaluation questions
- Enter the credits being claimed
- Press “submit”

Your certificate will automatically be emailed to you. Problems or questions? Contact Courtney Wille, in the SWOG operations office at cwille@swog.org. To keep track of your credits during the meeting, use the form on the next page.

Group Meeting Target Audience and Educational Objectives

SWOG meets semi-annually to keep its members abreast of group science. The target audience for these meetings are physicians, nurse oncologists and clinical research associates.

The educational objectives of these meetings are: to educate attendees about active and proposed studies so that they may implement the studies at their local institutions; to educate attendees about new treatments and prevention strategies that are available; to identify areas that can be improved in cancer research and study implementation and educate attendees on the best ways to implement the solutions at the local level.

These objectives apply to the following areas: Cancer Control and Prevention, including Cancer Care Delivery Committee, Symptom Control and Quality of Life Committee, Prevention & Epidemiology Committee, Cancer Survivorship Committee; Genitourinary Committee; Early Therapeutics & Rare Cancers Committee; Myeloma Committee; Melanoma Committee; Surgery Committee; Radiation Oncology Committee; Plenary Sessions Part I and II; Leukemia Committee; Breast Committee; Gastrointestinal Committee; Lung Committee, and Lymphoma Committee.

Continuing Medical Education Credit

The Hope Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Hope Foundation designates this live activity for a maximum of 22.0 AMA PRA Category 1 Credits.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Speaker and Planner CME Disclosure Information

Each speaker and planner for The Hope Foundation - CME courses has been requested to complete a Faculty Disclosure Form prior to the activity in accordance with ACCME standards. THF strives to provide accurate and up-to-date information regarding affiliations or interests that might be perceived as a potential conflict of interest for those who control CME content. Please see the disclosure handout available at the SWOG self-service and onsite registration desks. Best attempts will also be made to provide up to date information on introductory slides at each CME session.
New Procedures for CME Credit

We’ve gone paperless! SWOG no longer requires members to submit paper forms to obtain CME credits.

Getting your credits online is easy:
- Visit: [http://swog.org/Members/CMECertification.asp](http://swog.org/Members/CMECertification.asp)
- Complete the evaluation questions
- Enter the credits being claimed
- Press “submit”

Your certificate will automatically be emailed to you.

Problems or questions? Contact Courtney Wille in the SWOG operations office at cwille@swog.org.

To keep track of your credits during the meeting, use the form below.

### THURSDAY, SEPTEMBER 15, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Available</th>
<th>Actual</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am – 10:00 am</td>
<td>Cancer Care Delivery Committee</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>10:00 am – 12:15 pm</td>
<td>Early Therapeutics &amp; Rare Cancers Committee</td>
<td>2.25</td>
<td></td>
</tr>
<tr>
<td>10:15 am – 12:15 pm</td>
<td>Cancer Survivorship Committee</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>12:30 pm – 2:30 pm</td>
<td>Symptom Control &amp; Quality of Life Committee</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>3:00 pm – 4:30 pm</td>
<td>Plenary I (Translational Medicine)</td>
<td>1.5</td>
<td></td>
</tr>
</tbody>
</table>

### FRIDAY, SEPTEMBER 16, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Available</th>
<th>Actual</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am – 9:30 am</td>
<td>Prevention and Epidemiology Committee</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>9:30 am – 11:30 am</td>
<td>Melanoma Committee</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>9:30 am – 11:30 am</td>
<td>Surgery Committee</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>9:45 am – 11:45 am</td>
<td>Patient Reported Outcome Symposium</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>12:00 pm – 2:00 pm</td>
<td>Plenary II (General)</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>2:30 pm – 4:30 pm</td>
<td>Barlogie-Salmon Myeloma Committee</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>4:00 pm – 7:00 pm</td>
<td>Lymphoma Committee</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>4:00 pm – 7:00 pm</td>
<td>Lung Committee</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>4:30 pm – 6:30 pm</td>
<td>GI Committee</td>
<td>2.0</td>
<td></td>
</tr>
</tbody>
</table>

### SATURDAY, SEPTEMBER 17, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Available</th>
<th>Actual</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 am – 11:30 am</td>
<td>Radiation Oncology Committee</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>9:30 am – 11:30 am</td>
<td>Leukemia Committee</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>9:30 am – 12:30 pm</td>
<td>GU Committee</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>9:30 am – 12:30 pm</td>
<td>Breast Committee</td>
<td>3.0</td>
<td></td>
</tr>
</tbody>
</table>

**Total Possible Credits** 22.00
Tweet the meeting!

It’s our 60th anniversary. That’s worth a tweet!
Tag your 2016 meeting news and photos with

#SWOGOne

and

#SWOGturns60

Find the live stream of tagged Twitter updates on SWOG.org.

Follow SWOG at twitter.com/SWOG. Our username is @SWOG

#HaveAGreatMeeting
Hotel Safety Deposit Boxes: For your convenience, safety deposit boxes are available at the front desk for your valuables. Please do not leave valuables in your room.

Recreational Facilities: The fitness center offers a variety of exercise equipment, free weights, treadmills, and more, exclusively for hotel guests. *It is open 24 hours a day.*

Hotel Restaurants and Lounges: Stetsons Modern Steak & Sushi: Non-traditional steakhouse experience in a comfortable urban setting, specializing in steaks and seafood. *Restaurant is open daily from 5:00 p.m. - 11:00 p.m.*

American Craft Kitchen & Bar: Regionally inspired by all corners of the country, they offer an approachable dining experience with handcrafted food and drink. This atrium restaurant is the perfect stop for breakfast or lunch. *Open daily from 6:00 a.m. - 3:00 p.m.*

Market Chicago: Offers breakfast, lunch or dinner for a quick meal or coffee to go. *Open 24 hours a day.*

DaddyO’s Pub & Game Room: Corner pub featuring juicy burgers, local brews and wall-to-wall entertainment. *Open 5:00 p.m. - 1:00 a.m.*

The BIG Bar features the longest free-standing bar in North America and specializes in a wide variety of cocktails, wines, champagnes and cognacs and snacks. Open daily at 5:00 p.m.

In-room dining is available from 6:00 a.m. - 12:00 a.m. daily.

Business Center: The Business Center is located on the Purple level in the East Tower of the hotel. It is open 24 hours a day, 7 days a week. The Business Center offers fax machines, computer services, color copies, mail drop, Internet access and photocopying.

Ground Transportation: A taxi ride from O'Hare International Airport to the hotel is approximately $35.00 one-way.

A taxi ride from Midway International Airport to the hotel is approximately $30.00 one-way.

Valet parking at the hotel is a maximum of $65.00 per day for hotel guests.

Temperature: The average high for September is 75 degrees and the average low is 54 degrees.

AREA ATTRACTIONS:
- Adler Planetarium and Astronomy Museum
- Architectural Boat Tours
- Art Institute of Chicago
- Brookfield Zoo
- Chicago ArchiCenter
- Chicago Architecture Foundation
- Chicago Botanic Garden
- Field Museum of National History
- John G. Shedd Aquarium
- John Hancock Center Observatory
- Millennium Park
- Museum of Contemporary Art
- Museum of Science and Industry
- Rockefeller Memorial Chapel
- Sears Tower Skydeck

Local Restaurants:
( *The hotel concierge can assist with reservations and suggestions*)
- Alinea - Eclectic
- Atwood Cafe - American
- Bistro 110 - Continental
- Cape Cod Room - Seafood
- Mia Francesca - Italian
- Mon Ami Gabi - French
- Shaw's Crab House and Blue Crab Lounge - Seafood
- Silver Cloud - American
- Spiaggia - Italian
Hyatt Regency Chicago

Stetson A-F Meeting Rooms located on the Purple Level of the West Tower (one level below the Gold Level). Business Center and Package Pick-Up located on the Purple Level of the East Tower.
SWOG Fall 2016 Group Meeting

Wednesday, September 14, 2016 • Group Meeting Registration & Information Desk • 1:00 p.m. – 5:00 p.m.
Regency Foyer (Gold Level, West Tower)

10:30 A.M. – 12:30 P.M.
**ORP Executive Committee**
(COMMITTEE MEMBERS ONLY)
- Soldier Field
(Bronze Level, West Tower)
12:00 P.M. – 1:45 P.M.
**Nursing Research Subcommittee**
- Haymarket
(Bronze Level, West Tower)
1:00 P.M. – 2:00 P.M.
**NCPOR Workshop Check-In**
- Regency A Foyer
(Gold Level, West Tower)
- Soldier Field
(Bronze Level, West Tower)

1:00 P.M. – 5:00 P.M.
**SoCRA Certification Examination**
(Registration Required)
- Gold Coast
(Bronze Level, West Tower)
1:30 P.M. – 5:00 P.M.
**SWOG NCPOR Research Base Clinical Trials Workshop**
- Regency AB
(Gold Level, West Tower)
2:00 P.M. – 3:00 P.M.
**SWOG Tissue Banking Meeting**
(Invitation Only)
- Soldier Field
(Bronze Level, West Tower)

3:00 P.M. – 5:00 P.M.
**Task Force on Palliative Medicine and Advance Care Planning**
(1st hour is open, 2nd hour is closed)
- Water Tower
(Bronze Level, West Tower)
3:30 P.M. – 5:30 P.M.
**Hope Foundation Board Meeting**
(Board Members Only)
- New Orleans
(Gold Level, West Tower)

4:30 P.M. – 5:30 P.M.
**ORP Liaison Subcommittee**
(Formerly Disease & Discipline & Research)
- Comiskey
(Bronze Level, West Tower)
5:30 P.M. – 7:30 P.M.
**Site Operations**
(Formerly Head CRA – Open Session)
- Acapulco
(Gold Level, West Tower)
5:30 P.M. – 8:00 P.M.
**NCPOR Research Base Executive Committee Meeting**
(Committee Members Only)
- Regency C
(Gold Level, West Tower)

Thursday, September 15, 2016 • Group Meeting Registration & Information Desk • 7:00 a.m. – 5:00 p.m.
Regency Foyer (Gold Level, West Tower)

7:00 A.M. – 5:00 P.M.
**Hope Foundation Desk**
- Regency Foyer
(Gold Level, West Tower)
7:00 A.M. – 5:00 P.M.
**60th Anniversary Exhibits**
- Hong Kong and Toronto
(Gold Level, West Tower)
7:00 A.M. – 4:00 P.M.
**Pharmaceutical Exhibits**
- Toronto

7:00 A.M. – 8:00 A.M.
**Patient Advocates Committee Meeting**
(Committee Members Only)
- New Orleans
(Gold Level, West Tower)
7:30 A.M. – 8:00 A.M.
**Jeri & Noboru Oishi Symposium Check-In**
(Nurse and CRA Symposium)

8:00 A.M. – 10:00 A.M.
**CANCER CARE DELIVERY COMMITTEE**
- Michigan
(Bronze Level, East Tower)
8:00 A.M. – 10:00 A.M.
**Quality Initiative Meeting**
(Committee Members Only)
- Haymarket

**ALL-CAPS Meetings Receive CME Credits**
Thursday, September 15, 2016

10:00 A.M. – 12:00 P.M.

Digital Engagement Committee
- Water Tower
  (Bronze Level, West Tower)

10:00 A.M. – 12:15 P.M.

EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE
- Regency C
  (Gold Level, West Tower)

10:15 A.M. – 12:15 P.M.

CANCER SURVIVORSHIP COMMITTEE
- Michigan
  (Bronze Level, East Tower)

12:30 P.M. – 2:00 P.M.

ORP Open Forum
- Regency D
  (Gold Level, West Tower)

12:30 P.M. – 2:30 P.M.

SYMPTOM CONTROL AND QUALITY OF LIFE COMMITTEE
- Michigan
  (Bronze Level, East Tower)

2:00 P.M. – 3:00 P.M.

Plenary Reception
(Desserts and Coffee)
- Regency Foyer
  (Gold Level, West Tower)

2:00 P.M. – 3:00 P.M.

ORP Education Subcommittee
(Formerly Education & Program)
- Acapulco
  (Gold Level, West Tower)

3:00 P.M. – 4:30 P.M.

PLENARY I
(TRANSLATIONAL MEDICINE)
- Regency A-C
  (Gold Level, West Tower)

3:00 P.M. - 5:00 P.M.

Patient Advocates Committee Meeting
(Committee Members Only)
- Picasso
  (Bronze Level, West Tower)

International SWOG Sites Meeting
(Invitation Only)
- Water Tower
  (Bronze Level, West Tower)

4:30 P.M. - 6:30 P.M.

Lymphoma Working Group Meeting
(Committee Members Only)
- San Francisco
  (Gold Level, West Tower)

5:00 P.M. – 6:30 P.M.

Bone Marrow & Stem Cell Transplantation Committee
- Gold Coast
  (Bronze Level, West Tower)

5:00 P.M. – 6:30 P.M.

Eagle II Reception
(Committee Members Only)
- Comiskey
  (Bronze Level, West Tower)

5:00 P.M. – 7:00 P.M.

GI Working Group Meeting
- San Francisco
  (Gold Level, West Tower)

5:00 P.M. – 7:00 P.M.

Conflict Management Committee
- Haymarket
  (Bronze Level, West Tower)

7:00 P.M. – 9:00 P.M.

Latin American Symposium
(Invitation Only)
- Water Tower
  (Bronze Level, West Tower)

ALL-CAPS Meetings Receive CME Credits

---

SWOG Snapshot:

12,000+ members

46 states

1,000+ sites

6 international partners
## Schedule of Events

**Friday, September 16, 2016 • Group Meeting Registration & Information Desk • 7:00 a.m. – 5:00 p.m.**  
**Regency Foyer (Gold Level, West Tower)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 7:00 A.M. – 5:00 P.M. | **Hope Foundation Desk**  
|               | ■ Regency Foyer  
|               | (Gold Level, West Tower)  
| 7:00 AM – 5:00 PM | **60th Anniversary Exhibits**  
|               | ■ Hong Kong and Toronto  
|               | (Gold Level, West Tower)  
| 7:00 A.M. – 4:00 P.M. | **Pharmaceutical Exhibits**  
|               | ■ Toronto  
|               | (Gold Level, West Tower)  
| 7:30 – 9:30 A.M. | **Imaging Committee**  
|               | (Committee Members Only)  
|               | ■ New Orleans  
|               | (Gold Level, West Tower)  
| 7:30 – 9:30 A.M. | **SWOG Data and Safety Monitoring Committee**  
|               | (Committee Members Only)  
|               | ■ San Francisco  
|               | (Gold Level, West Tower)  
| 7:30 – 9:30 A.M. | **PREVENTION AND EPIDEMIOLOGY COMMITTEE**  
|               | ■ Michigan  
|               | (Bronze Level, East Tower)  
| 7:30 – 11:00 A.M. | **Myloma Working Group Meeting**  
|               | (Working Group Members Only)  
|               | ■ Wrigley  
|               | (Bronze Level, West Tower)  
| 8:00 – 9:00 A.M. | **Professional Review Committee**  
|               | (Committee Members Only)  
|               | ■ Haymarket  
|               | (Bronze Level, West Tower)  
| 8:30 – 9:00 A.M. | **Drug Information Subcommittee and Working Group**  
|               | (Working Group Members Only)  
|               | ■ Columbian  
|               | (Bronze Level, West Tower)  
| 9:00 – 11:00 A.M. | **Adolescent and Young Adult (AYA) Committee**  
|               | ■ Crystal C  
|               | (Green Level, West Tower)  
| 9:00 A.M. – 12:00 P.M. | **GU Organ Site Meeting**  
|               | (Working Group Members Only)  
|               | ■ Plaza Ballroom  
|               | (Green Level, East Tower)  
| 9:30-10:30 AM | **S1403 Protocol Update Meeting**  
|               | ■ Gold Coast  
|               | (Bronze Level, West Tower)  
| 9:30 – 11:30 A.M. | **MELANOMA COMMITTEE**  
|               | ■ Crystal B  
|               | (Green Level, West Tower)  
| 9:30 – 11:30 A.M. | **SURGERY COMMITTEE**  
|               | ■ Crystal A  
|               | (Green Level, West Tower)  
| 9:45 – 11:45 A.M. | **Patient Reported Outcome Symposium: Approaches, Tools, Electronic Data Capture**  
|               | ■ Regency D  
|               | (Gold Level, West Tower)  
| 10:00 – 11:30 A.M. | **Quality Assurance Committee Meeting**  
|               | (Committee Members Only)  
|               | ■ San Francisco  
|               | (Gold Level, West Tower)  
| 11:00 A.M. – 12:00 P.M. | **NCORP Principal Investigator Meeting**  
|               | ■ Gold Coast  
|               | (Bronze Level, West Tower)  
| 12:00 – 2:00 P.M. | **Plenary Reception**  
|               | (Light Hors D’oeuvres)  
|               | ■ Regency Foyer  
|               | (Gold Level, West Tower)  
| 2:00 – 3:00 P.M. | **PLENARY II (GENERAL)**  
|               | ■ Regency A-C  
|               | (Gold Level, West Tower)  
| 2:15 – 3:45 P.M. | **New Investigator Round Table Session**  
|               | (Open for Drop-Ins)  
|               | ■ Columbian  
|               | (Bronze Level, West Tower)  
| 2:15 – 3:45 P.M. | **S1400 Update Meeting**  
|               | ■ Regency D  
|               | (Gold Level, West Tower)  
| 3:45 – 4:30 P.M. | **VA Working Group**  
|               | (Invitation Only)  
|               | ■ Haymarket  
|               | (Bronze Level, West Tower)  

**ALL-CAPS Meetings Receive CME Credits**
Schedule of Events

Friday, September 16, 2016, continued

2:30 – 4:30 P.M.
BARLOGIE-SALMON MYELOMA COMMITTEE
Michigan
(Bronze Level, East Tower)

2:30 – 5:30 P.M.
GU Symposium: “The Role of Cytoreductive Surgery in Metastatic GU Cancer”
Crystal C
(Green Level, West Tower)

2:30– 5:30 P.M.
Breast Working Group Meeting (Working Group Members Only)
Acapulco
(Gold Level, West Tower)

3:00 – 5:00 P.M.
ORP Planning Meeting
(Committee Members Only)
New Orleans
(Gold Level, West Tower)

3:30 – 4:30 P.M.
S1316 Protocol Meeting
San Francisco
(Gold Level, West Tower)

4:00- 6:00 P.M.
Pharmaceutical Sciences Committee
Water Tower
(Bronze Level, West Tower)

4:30 – 6:30 P.M.
GI COMMITTEE
Regency B
(Gold Level, West Tower)

4:30 – 6:30 P.M.
GI COMMITTEE
Regency B
(Gold Level, West Tower)

4:30 – 6:30 P.M.
Pharmaceutical Sciences Committee
Water Tower
(Bronze Level, West Tower)

4:30 – 6:30 P.M.
GI COMMITTEE
Regency B
(Gold Level, West Tower)

4:30- 6:30 P.M.
Pharmaceutical Sciences Committee
Water Tower
(Bronze Level, West Tower)

4:30 – 6:30 P.M.
GI COMMITTEE
Regency B
(Gold Level, West Tower)

4:00 – 7:00 P.M.
LYMPHOMA COMMITTEE
Regency A
(Gold Level, West Tower)

4:00 – 7:00 P.M.
LYMPHOMA COMMITTEE
Regency A
(Gold Level, West Tower)

5:30 – 7:30 P.M.
GU Kickoff Meeting for S1602
Crystal A
(Green Level, West Tower)

6:00 – 9:00 P.M.
60th Anniversary Reception
Regency CD
(Gold Level, West Tower)

6:00 – 9:00 P.M.
60th Anniversary Reception
Regency CD
(Gold Level, West Tower)

7:15 – 8:00 P.M.
60th Anniversary Reception
Regency CD
(Gold Level, West Tower)

7:30 – 9:30 P.M.
GU Kickoff Meeting for S1602
Crystal A
(Green Level, West Tower)

8:30 – 10:30 P.M.
60th Anniversary Reception
Regency CD
(Gold Level, West Tower)

8:30 – 10:30 P.M.
60th Anniversary Reception
Regency CD
(Gold Level, West Tower)

8:30 – 10:30 P.M.
60th Anniversary Reception
Regency CD
(Gold Level, West Tower)

8:30 – 10:30 P.M.
60th Anniversary Reception
Regency CD
(Gold Level, West Tower)

8:30 – 10:30 P.M.
60th Anniversary Reception
Regency CD
(Gold Level, West Tower)

9:30 – 11:30 A.M.
LEUKEMIA COMMITTEE
Regency C
(Gold Level, West Tower)

9:30 – 11:30 A.M.
LEUKEMIA COMMITTEE
Regency C
(Gold Level, West Tower)

9:30 – 11:30 A.M.
LEUKEMIA COMMITTEE
Regency C
(Gold Level, West Tower)

9:30 – 11:30 A.M.
LEUKEMIA COMMITTEE
Regency C
(Gold Level, West Tower)

9:30 – 11:30 A.M.
LEUKEMIA COMMITTEE
Regency C
(Gold Level, West Tower)

9:30 – 11:30 A.M.
LEUKEMIA COMMITTEE
Regency C
(Gold Level, West Tower)

9:30 – 11:30 A.M.
LEUKEMIA COMMITTEE
Regency C
(Gold Level, West Tower)

9:30 – 11:30 A.M.
LEUKEMIA COMMITTEE
Regency C
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

9:30 A.M. – 12:30 P.M.
BREAST COMMITTEE
Regency D
(Gold Level, West Tower)

ALL-CAPS Meetings Receive CME Credits
SWOG Administrative Committees

Adolescent & Young Adults
Chair: Mark A. Lewis, M.D.

Board of Governors
Chair: Charles D. Blanke, M.D.

Bone Marrow and Stem Cell Transplantation Committee
Chair: Patrick J. Stiff, M.D.

Conflict Management Committee
Chair: Paul Okunieff, M.D.

Data & Safety Monitoring Committee
Chair: Lawrence E. Flaherty, M.D.

Digital Engagement Committee
Chair: Don S. Dizon, M.D.

Imaging Committee
Chair: Lawrence H. Schwartz, M.D.

Membership Committee
Chair: James K. Weick, M.D.

Oncology Research Professionals Committee
Chair: Keisha Humphries, R.N., B.S.N.

Patient Advocate Committee
Chair: Rick Bangs, M.B.A.

Pharmaceutical Sciences Committee
Co-Chair: Siu-Fun Wong, Pharm.D.
Co-Chair: Susan Kadlubar, Ph.D.

Publications Committee
Chair: Hagen Kennecke, M.D.

Professional Review Committee
Chair: Primo N. Lara, Jr., M.D.

Quality Assurance Committee
Chair: Manuel Valdivieso, M.D.

Radiation Oncology Committee
Chair: Paul Okunieff, M.D.

Surgery Committee
Chair: George H. Yoo, M.D.

Future Meeting Dates

<table>
<thead>
<tr>
<th>Year</th>
<th>April</th>
<th>October</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>26-29</td>
<td>11-14</td>
</tr>
<tr>
<td></td>
<td>San Francisco, CA</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>2018</td>
<td>11-14</td>
<td>3-6</td>
</tr>
<tr>
<td></td>
<td>San Francisco, CA</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>2019</td>
<td>24-27</td>
<td>2-5</td>
</tr>
<tr>
<td></td>
<td>San Francisco, CA</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>2020</td>
<td>22-25</td>
<td>23-26</td>
</tr>
<tr>
<td></td>
<td>San Francisco, CA</td>
<td>Chicago, IL</td>
</tr>
</tbody>
</table>
Special Symposia
Jeri and Noboru Oishi Symposium

Thursday, September 15, 2016 • Regency A+B • 7:30 a.m. – 12:00 p.m.

7:30 – 8:00 AM
Registration
8:00 – 8:10 AM
Welcome and Introductions
Keisha Humphries
R.N., B.S.N., M.H.C.L., O.C.N.
Chair, Oncology Research Professionals Committee Wichita
NCI Community Oncology Program (NCORP) Via Christi Hospitals, Wichita.
8:10 – 8:25 AM
SWOG Update
Phyllis Goodman, M.S.
SWOG Statistical Center
8:25 – 8:50 AM
Implementation and Use of CIRB
Amanda Putnick, B.A., C.I.P.
CIRB Administrator
Emmes Corp
8:50 – 9:50 AM
LUNG-MAP – Objectives, Eligibility & Treatment
Fred Hirsch, M.D.
Professor of Medicine and Pathology
Pia and Fred R. Hirsch Endowed Chair
Associate Director, University of Colorado Cancer Center
9:50 – 10:00 AM
Break
10:00 – 11:00 AM
AML, the Older Adult and Clinical Trials
Harry Erba, M.D.
Professor of Medicine and Director
University of Alabama at Birmingham, Hematology
Malignancy Program SWOG Leukemia Committee, Chair
11:00 AM – 12:00 PM
Yes, It Really Is All About Us!
Cheryl Jernigan, C.P.A.
Patient Advocate
SWOG Patient Advocate Committee
SWOG Cancer Prevention & Epidemiology Committee
Susan G. Komen Advocates in Science Program, Steering Committee

Sequencing local and systemic therapy for metastatic colorectal cancer
Educational Session: Surgery Committee
Friday, September 16, 2016 • Crystal A • 9:30 – 1:30 a.m.

Local therapy
Surgery
Primary tumor resection:
Nancy You, M.D.
Metastatecomy
Liver: Claudius Conrad, M.D.
Lung: Jae Kim, M.D.
Radiation:
Timur Mitin, M.D. Ph.D.

Systemic therapy:
Chemotherapy
Philip A. Philip, M.D., Ph.D.
Division of Hematology/Oncology,
Wayne State University/Karmanos Cancer Institute
Nancy You, M.D.
Department of Surgical Oncology,
MD Anderson Cancer Center
Claudius Conrad, M.D.
Department of Surgical Oncology,
MD Anderson Cancer Center
Jay Kim, M.D.
Department of Surgical Oncology,
City of Hope
Timur Mitin, M.D. Ph.D.
Assistant Professor, Department of Radiation Medicine, Oregon Health and Science University

Patient-Reported Outcomes Symposium
Friday, September 16, 2016
Regency D
9:45-11:45 a.m.
1. Overview of PRO, emerging practices (Cella)
2. Introduction to PRO-CTCAE, use in cooperative group studies (Basch)
3. PRO in SWOG (Unger)
4. The NCI view of PRO (Minasian)
Panel discussion
Special Symposia

Oncology Research Professionals Open Forum

Thursday, September 15, 2016 • Regency D • 12:30-2:00 pm

- QA Audit reviews and SAEs reporting
- Regulatory review
- Data management tips/tools
- Investigational agent audit Q & A
- Specimen preparation and shipment
- SWOG federal and CTI non-federal reimbursements
- Hot topics in site administration
- Committee discussions
- Lung-MAP trial: S1400 – Q & A

We work in cancer research for a reason.
What’s yours?

Tell your SWOG story for StoryCorps, America’s oral history project.

Your story could be heard on the SWOG website – or be archived in the Library of Congress!

It’s easy.

- Download the StoryCorps app at https://storycorps.me/
- Choose someone to interview.
- Pick great questions. Find a quiet place to record. Listen closely.
- When you’re finished, share your interview with the world using the hashtag #SWOGturns60

StoryCorps.org • We believe every story matters.
Barlogie-Salmon Myeloma Committee

Committee Leadership

Chair: Robert Z. Orlowski, M.D., Ph.D.
Vice-Chair: Brian G.M. Durie, M.D.
Executive Officer: Susan M. O’Brien, M.D.
Statisticians: Antje Hoering, Ph.D.
Rachael Sexton, M.S.
Kari Chansky, M.S.

Scientific Leadership

Translational Medicine: Joshua Epstein, D.Sc.
Radiation: TBD
Surgery: J. Sybil Biermann, M.D.
Imaging: Saad Z. Usmani, M.D.
Eric M. Rohren, M.D., Ph.D.
Pathology: Robert B. Lorsbach, M.D., Ph.D.

Early Therapeutics: Frits van Rhee, M.D., Ph.D.

Designates

NCORP Representative: George F. Geels, Jr., M.D.
Data Coordinators: Jeri Jardine
Laura Kingsbury, M.R.T.

Oncology Research Professionals:

CRA: TBD

Nurse: Deborah A. Halk, R.N.
Patient Advocate: Jack Aiello
Pharmaceutical Science: Lara M. Au, Pharm.D.
Craig Elg, Pharm.D.
Protocol Coordinator: Cara Laubach, M.I.M.

Active Studies


CTSU/E1A11. “Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURa-tion Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).” Dr. J. Zonder. Activated by ECOG: 11/13/13; Activated by SWOG: 2/1/14.

Closed Studies


Proposed Studies

S1503. “Randomized Phase II Multicenter Non-Inferiority Trial of Xarelto versus Low Molecular Weight Heparin for Prevention of Thromboembolism in Patients Being Treated with an Immunomodulatory-Based Regimen for Multiple Myeloma.” David Calverley, Jamie Meyers, and Emma Scott.

S1606. “Randomized Phase III Study of Lenalidomide (L) vs. Lenalidomide + ixazomib (NSC-767907) (LI) as Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma (MM).” Dr. J. Shah.

S1611. “A Phase II Non Randomized Study of 11-IF4 Chimeric Monoclonal Ab added to standard treatment in Untreated Subjects with Light Chain (AL) Amyloidosis.” Dr. S. Lentzsch.

S1617. “A Randomized Phase I/II Study of Ibrutinib with Daratumumab vs. Ibrutinib Alone in Patients with Previously Untreated Waldenström’s Macroglobulinemia (WM).” Dr. S. Ailawadhi.

SXXXX. “A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis.” Dr. E. Scott.

Open Forum Discussion Working Groups

Amyloidosis Working Group update
Waldenström’s Working Group update
Myeloma Translational Medicine Subcommittee update
Breast Committee

Committee Leadership
Chair:
Gabriel N. Hortobagyi, M.D.
Vice-Chair:
Debasish Tripathy, M.D.
Executive Officer:
Julie R. Gralow, M.D.
Statisticians:
William E. Barlow, Ph.D.
Danika Lew, M.A.
Jieling Miao, M.S.

Scientific Leadership
Translational Medicine:
Daniel F. Hayes, M.D.
Radiation Oncology:
Reshma Jagsi, M.D.
Surgery:
Christine Lee, M.D.
Imaging:
Anne F. Schott, M.D.

Pathology:
Allen M. Gown, M.D.
Peggy L. Porter, M.D.

Early Therapeutics:
George Somlo, M.D.

Designates
Cancer Control Liaisons:
Carol J. Fabian, M.D.
(Cancer Survivorship)
Dawn L. Hershman, M.D.
(Cancer Care Delivery)
TBD (Prevention)
Helen K. Chew, M.D.
(Symptom Control & QOL)

NCORP Representative:
Melanie E. Royce, M.D., Ph.D.

Data Coordinators:
Jennie Barrett
Jacqueline Scurlock
Sean O’Bryan
Larry Kaye
Iris Syquia

Oncology Research Professionals:
CRA:
Karyn N. Hart, C.C.R.P.

Nurses:
Dorothy Coleman, R.N., M.S.
Kathy L. Czaplicki, R.N., M.S.N.
Caralee Applequist, R.N., M.S.N.

Patient Advocates:
Ginny Mason, R.N.
Elda Railey

Pharmaceutical Science:
Jessie Modlin, Pharm.D.
Rivka Siden, Pharm.D.

Protocol Coordinator:
Megan Hardin

Agenda • Saturday, September 17, 2016 • Regency D • 9:30 a.m. – 12:30 p.m.

9:30 – 9:35 AM
Welcome and Introductions
Gabriel Hortobagyi, M.D.
and Debu Tripathy, M.D.

9:35 – 10:04 AM
Breast Committee Mini-Symposium “Energy Balance and Breast Cancer Outcomes”
Jennifer Ligibel, MD
Dana-Farber Cancer Institute

9:35 – 10:05 AM
Design of definitive trials testing adjuvant weight loss for early stage breast cancer –
Jennifer Ligibel, MD

10:05 – 10:15 AM
Conducting behavioral interventions within SWO
Heather Greenlee, ND, PhD

10:15 – 10:25 AM
Balance and breast cancer risk: Potential biological mechanisms
Marian Neuhouser, PhD, RD

10:25 – 10:40 AM
Panel discussion and audience Q & A

10:40 – 10:45 AM
Publications update
Bill Barlow, Ph.D.

10:45 – 11:05 AM
Results of SWOG S0800
Zeina Nahleh, MD and
Lajos Pusztai, MD, PhD

11:05 – 11:30 AM
Update of open SWOG and CTSU trials - All

11:30 AM – 12:50 PM
Studies in Development - All

12:15 – 12:30 PM
New Business - All

12:30 PM
Adjourn
Breast Committee

Active Studies


S1416. “Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple Negative Breast Cancer (TNBC) and BRCA Mutation-Associated Breast Cancer.” Drs. Rodler and Sharma. Activated: 7/7/16.


CTSU/NSABP B-55. “A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.” Dr. Sharma. Activated: 7/3/14.


Active Cancer Control Studies


S1415CD. “A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Or-der Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia”. Drs. Ramsey, Hershman, Lyman and Sullivan. Activated: TBD.


Closed Studies


S1411. “Phase II Randomized Trial of Adjuvant Vaccine Therapy in Patients with High-Risk HER2-Positive Breast Cancer.” Dr. Mittendorf.

S1418. “A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >1 cm Residual Invasive Cancer or Positive Lymph Nodes (pNmic) After Neoadjuvant Chemotherapy.” Drs. Pusztai, Sharma and Mammen.

Cancer Control and Prevention Committees

Committee Leadership
Vice-Chair NCORP:
Dawn L. Hershman, M.D., M.S.*
Cancer Care Delivery
Committee Co-Chairs:
Dawn L. Hershman, M.D., M.S.*
Scott D. Ramsey, M.D., Ph.D.*
Cancer Survivorship
Committee Co-Chairs:
Carol J. Fabian, M.D.*
Robert S. Krouse, M.D., FACS*
Prevention and Epidemiology
Committee Co-Chairs:
Banu Arun, M.D.*
Marian Neuhouser, Ph.D., R.D.*
Symptom Control & QOL Committee Co-Chairs:
Michael Fisch, M.D., Ph.D.*
Norah Lynn Henry, M.D., Ph.D.*
Executive Officers:
Katherine D. Crew, M.D.*
Gary H. Lyman, M.D.*
Senior Advisor:
Frank L. Meyskens, Jr., M.D.*

Statistics:
Garnet Anderson, Ph.D.*
William E. Barlow, Ph.D.*
Katherine Guthrie, Ph.D.*
Cathy Tangen, Dr.P.H.*
Joseph M. Unger, Ph.D.*
Kathryn B. Arnold, M.S.*
Amy K. Darke, M.S.*
Phyllis J. Goodman, M.S.*
Danika Lew, M.A.*
Anna Moseley, M.S.*
Cathee Till, M.S.*

Administrative Lead (Statistical Center):
Monica Yee, B.A., C.C.R.P.*

Scientific Leadership
NCORP Representative:
Mark A. O’Rourke, M.D.*
Radiation Therapy Committee:
Louis “Sandy” Constine, M.D.
Surgery Committee:
Robert S. Krouse, M.D., FACS*
Translational Medicine:
James (Jimmy) Rae, Ph.D.*

Liaisons:
Breast Committee:
Carol J. Fabian, M.D.
(Survivorship)*
Norah Lynn Henry, M.D. Ph.D
(Symptom Control & QOL)*
Dawn Hershman, M.D. M.S.
(CCD)*
Banu Arun, M.D. (Prevention)*

Gastrointestinal Committee:
Afsaneh Barzi, M.D.
Gastrointestinal Committee Colon:
Jason, Zell, D.O.
Genitourinary Committee:
Peter J. Van Veldhuizen, Jr., M.D.
International Liaison:
Kathy S. Albain, M.D.*
Lung Committee:
Gary E. Goodman, M.D.*
Lymphoma Committee: TBD
Melanoma Committee:
Sancy Leachman, M.D., Ph.D.

Designates
Oncology Research Professionals
Clinical Research Associates:
Connie Szczepanek, R.N.
Joyce N. Tull, R.N.
Amanda R. Dinsdale, M.H.A., C.C.R.C.
Mindy Whisnant, C.C.R.P.
Nurses:
Joan Long, R.N.
Michaela S. Sherbec, R.N.
Pharmaceutical Science Committee:
Manj Randhawa, Pharm.D.
Siu-Fun Wong, Pharm.D.*
Susan A. Kadlub, Ph.D.

Statistical Center Support and Data Coordinators:
Karen Anderson*
Monica Yee, C.C.R.P.*
Heidi Dong.*
Diane Liggett, C.C.R.P.*
Jennifer Patterson*
Roxanne Topacio, C.C.R.P.*

Patient Advocates:
T. Bradley Bott, M.B.A., C.C.R.P. (CCDR)
Amy Geschwender, Ph.D.
(Symptom Control & QOL)
Anna Gottlieb (Survivorship)
Sandra Jean Hamilton, R.N., M.E.D. (Recruitment/Retention)
Cheryl Jernigan (Prevention & Epidemiology)

Protocol Coordinator:
(Cancer Care Delivery; Prevention and Epidemiology Committees):
Patricia O’Kane*

Protocol Coordinator:
(Cancer Survivorship Committee):
Nicki Trevino

Protocol Coordinator:
(Symptom Control and Quality of Life Committee):
Dawne Wenzel, M.A.*

* Executive Committee Members and Staff
Cancer Care Delivery (CCD) Committee

Cancer Care Delivery Committee Co-Chairs:
Dawn L. Hershman, M.D., M.S | Scott D. Ramsey, M.D., Ph.D.

Presentations/Concepts:
Physician-Hospital Consolidation and Cancer Drug Costs. Rena Conti, P.D., University of Chicago
An Online Oncologist Q+A Platform to Improve Cancer Care Delivery. Nadine Housri, M.D.

New Concepts
S1620CD. “Randomized Multicenter Trial Comparing Total Healthcare Costs of Serum Tumor Marker Directed Disease Monitoring vs. Usual Care in Metastatic Breast and Colorectal Cancer Patients.” Melissa Accordino, M.D.

Use of New Anti-neoplastic Agents Post Approval: Population Characteristics and Outcomes. Afsaneh Barzi, M.D. and Alan Lyss, M.D.

Breast Cancer Endocrine Therapy Adherence Text Messaging Study (“BETA-Text”). Sarah Mougalian, M.D.

Health Insurance Coverage as a Potential Barrier to Enrollment in Cancer Clinical Trials. Josh Roth, Ph.D., MHA

CCD Approved Studies

Ongoing Database/Grant Funded Projects
Value of Information and SWOG Trials, PCORI Project. Dr. Ramsey, and J. Carlson, Ph.D.

Long-term Consequences of Intervention Following Receipt of Finasteride or Placebo in the Prostate Cancer Prevention Trial. Joseph Unger, PhD.

Ongoing Database Pilot Studies:
1. Ethnic Disparities Among Participants in SWOG Randomized Trials. Mariana Chavez, M.D.
2. Osteoporosis in Patients with Colorectal Cancer Enrolled on SWOG Trials. Afsaneh Barzi, M.D.
3. Deconstructing the Endpoints of SWOG Trials. Vinay Prasad, M.D.
4. Evaluating the Role of Geographic Location on Outcomes Among Patients Enrolled in SWOG Trials. Banu Symington, M.D.

Active Studies
S1007. “Update on Quality of Life and Economic Analysis Sub-study of Breast Protocol S1007.” Bill Barlow, Ph.D.
S1207, Cost Effectiveness Analysis of “Phase III Randomized, Placebo-controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One year of Everolimus in Patients with High-risk, Hormone Receptor-positive and HER2/neu Negative Breast Cancer.” Drs. Chavez-MacGregor.
S1417CD. “Implementation of a Prospective Financial Toxicity Assessment Tool in Patients with Metastatic Colorectal Cancer”. Dr. Shankaran.

PCORI Project: A Structured Approach to Prioritizing Cancer Research Using Stakeholders and Value of Information (VOI)

April 26-29, 2017
San Francisco, CA
Cancer Survivorship Committee

Cancer Survivorship Committee Co-Chairs:
Carol J. Fabian, M.D.  |  Robert S. Krouse, M.D.

Agenda • Thursday, September 15, 2016 • Michigan • 10:15 a.m. – 12:15 p.m.

Plenary
Exercise as a Countermeasure to Treatment-Related Toxicities in Cancer Survivors: Kerri Winters-Stone, Ph.D.

Approved Studies
S1501, “Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer.” Justin Floyd, D.O. and Monika Leja, M.D.

New Concepts
A Randomized Study of Aspirin in Addition to Non-Steroidal AI in Obese Subjects with Breast Cancer. Andrew Brenner, M.D., Ph.D.

Weight Loss in Newly Diagnosed Prostate Cancer. Jill Hamilton-Reeves, Ph.D., R.D.

Update on Pilots for New Concepts
Docosahexaenoic Acid (DHA) versus Placebo during Adjuvant Therapy for Prevention of Cognitive Dysfunction Pilot feasibility study (Secondary Committee Breast). Carol Fabian, M.D.

Activated Studies

A Phase II Trial of Flibanserin to Improve Desire in Women with Cancer. Don Dizon, M.D.

GU Survivorship: Peter Van Veldhuizen, M.D.

Sarcoma Survivorship: Lara Davis, M.D. and Laurence H. Baker, D.O.

Oncology Research Professionals Update:
Jamie Myers APRN, Ph.D.

Advocate Update: Rick Bangs and Anna Gottlieb.

Other Business

Lives improved.
Lives lengthened.
Lives saved.

SWOG
Leading cancer research. Together.
Prevention & Epidemiology Committee

Prevention Committee Co-Chairs:
Marian Neuhouser, Ph.D., R.D. | Banu Arun, M.D.

Agenda • Friday, September 16, 2016 • Michigan • 7:30-9:30 a.m.

Presentations:
1. Welcome and Opening Comments
   Dr. Marian Neuhouser and Dr. Banu Arun
2. Project ECHO: A Potential Model for Cancer Prevention
   Dr. Michelle Iandiorio
3. Use of social media in SWOG Prevention Studies
   Dr. Don Dizon

Active Studies

Closed Studies
S0000B, “Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium-SELECT Eye Endpoints (SEE) Phase III Ancillary Study to S0000- SELECT.” Drs. Christen, Glynn and Gaziano. Activated 7/1/04; Closed 7/31/15.

New Business
Concepts under development:
1. Several new concepts will be presented

Other Concepts to discuss:
1. Open discussion

Let’s Make More Time
Symptom Control & Quality of Life Committee

Symptom Control and QOL Committee Co-Chairs:
Michael J. Fisch, M.D., M.P.H.  |  Norah Lynn Henry, M.D., Ph.D.

Agenda • Thursday, September 15, 2016 • Michigan • 12:30 – 2:30 p.m.

Presentations (45 minutes):

Co-Chair Overview: Review summer call, current RFP

Keynote: Amy Geschwender: The Growing Role of the Patient Voice in Research Planning and Implementation

CIPN Mini-symposium (40 minutes)

New Business (20 minutes)

Updates on trials under development (15 minutes)

Update on Active Studies and Other Concepts in Development (20 minutes)

Active Studies


Closed Studies

S1007, “A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2 Negative Breast Cancer with Recurrence Score (RS) of 25 or less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer.” Drs. Kalinski and Gralow. Closed to accrual 10/1/15. Quality of Life and Economic Substudy closed to accrual 12/1/12.


Concepts in Development

S1600, “Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes.” Jill Hamilton- Reeves, PhD

S1614, “Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors”. Jessica Hwang, MD, MPH.

“Cognitive Rehabilitation Intervention during Cancer Treatment: Emerging from the Haze”. Arash Asher, MD; Jamie Myers, PhD, RN, AOCNS.

“A Phase II Randomized Placebo-Controlled Study to Evaluate the Use of vitamin K1 Topical Lotion in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors”. Drs. Wong, Ryan, Wade, & Moinpour

Other Active Studies with Symptom Control and QOL Component

S1207, “Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.” Dr. Chavez-MacGregor. Activated: 9/1/13.


CTSU/A021202, “Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors”. Dr. Phan. Activated: 1/15/14.

CTSU/A041202, “A Randomized Phase III Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (>/=65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)”. Dr. Coutre. Activated: 12/15/13. Closed to accrual 5/16/16.


Symptom Control & Quality of Life Committee


**CTSU/E1411.** “Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB -->R); Arm B =Rituximab+Bendamustine+ Bortezomib Followed by Rituximab Consolidation (RBV --> R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide +Rituximab Consolidation (RB --> LR) or Arm D = Rituximab+Bendamustine+ Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV --> LR)”. Dr. Till. Activated: 6/15/12.


**CTSU/E1A11.** “Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)”. Dr. Zonder. Activated: 2/1/14.

**CTSU/E2810.** “Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy”. Dr. Pal. Activated: 9/1/12.


**CTSU/E3A06.** “Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic Intermediate Dose Cytarabine Post-Remission Therapy, Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)”. Dr. Godwin. Activated: 8/15/12. Closed 1/22/2016.

**CTSU/E3A34.** “A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipiilimumab + Nivolumab at Progression vs. Ipiilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma”. Dr. Chmielowski. Activated: 12/15/09.

**CTSU/R0848.** “A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma”. Dr. Philip. Activated: 12/1/11. Closed 12/18/15.

**CTSU/R1010.** “A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma”. Dr. Leichman. Activated: 9/1/11.

**Committee Process**
Sign and/or correct the meeting attendance/contact list

**Communication issues**

**Announcements**

**NCORP Updates**
Early Therapeutics and Rare Cancers Committee

Committee Leadership
Chair: Razelle Kurzrock, M.D.
Executive Officer: Christopher W. Ryan, M.D.
Statisticians: Megan Othus, Ph.D. Melissa Plets, M.S. Cyrus Ebnesajjad, M.S.

Designates
Data Coordinators: Laura Kingsbury, M.R.T. Christine McLeod

Oncology Research Professionals:
CRA: Corrine Turrell, C.C.R.P.
Nurse: TBD

Pharmaceutical Science:
Siu-Fun Wong, Pharm.D.

Patient Advocate:
Marcia K. Horn, J.D.

Protocol Coordinator:
Cara Laubach, M.I.I.M.

Early Therapeutics Liaisons
Breast Committee Liaison: George Somlo, M.D.
Genitourinary Committee Liaison: Neeraj Agarwal, M.D.
Imaging:
Oliver Press, M.D.
Lung Committee Liaison: Shirish M. Gadgeel, M.D.

Lymphoma Committee Liaison: Daruka Mahadevan, M.D., Ph.D.
Melanoma Committee Liaison: Jeffrey A. Sosman, M.D.
Myeloma Committee Liaison: Frits van Rhee, M.D., Ph.D.

Presentations:
10:10AM – 10:30 AM:
“S1618: A Phase II Study of a selective JAK1 Inhibitor (INCB39110) in Subjects with Advanced Sarcomas,” Victor M. Villalobos, MD, PhD, Assistant Professor of Medicine, Director, Sarcoma Medical Oncology, Director, Target-based Therapeutics Team (T3), University of Colorado Denver, Anschultz Medical Campus.

10:50AM – 11:10AM:
“Updates in S1609: DART Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors: Emphasis on Biomarkers,” Sandip Patel, MD, Assistant Professor, UCSD Moores Cancer Center and Young K. Chae, MD, MPH, Assistant Professor, Northwestern University

11:10AM – 11:30AM:
“A Phase II study of Brentuximab Vedotin in CD30 + Systemic Mastocytosis and CMML,” Uma Borate, MD, MS, Assistant Professor, Acute Leukemia Translational Research Lead, Oregon Health & Science University and Aaron Gerds, MD, MS, Associate Staff, Hematology and Medical Oncology, Cleveland Clinic, Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Sanjay Mahadevan, MBBS, PhD.

12:05PM – 12:15PM:
“Panel Questions and Answers/ Open Discussion: Other New Business?,” Razelle Kurzrock, MD and Speakers Proposed Studies


S1618. “A Phase II Study of a selective JAK1 Inhibitor (INCB9110) in Subjects with Advanced Sarcomas,” V.M. Villalobos M.D., Ph.D.


SXXXX. “Randomized Phase
Early Therapeutics and Rare Cancers Committee

**Active Studies**

**CTSU/GOG-0286B, “A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer (NCT #0265687).”** Dr. K. Raghav.


**CTSU/ARST1321, “Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radio-tion Plus or Minus Pazopanib (NSC# 737754, IND# 118613)” Dr. V.M. Villalobos. *Activated by SWOG: 3/15/2016.*

**Closed Studies**


---

**Celebration 60!**

Visit our interactive exhibit on SWOG’s history and impact. And record your own stories, take a selfie, and post your dreams for SWOG’s future.

Find the special exhibits in the **Hong Kong** and **Toronto rooms**, near the main registration area, on **Thursday and Friday, Sept. 15 and 16**
Gastrointestinal Committee

Committee Leadership
Chair: Howard S. Hochster, M.D.
Vice-Chair: Heinz-Josef Lenz, M.D.
Executive Officer: Christopher W. Ryan, M.D.
Statisticians: Katherine Guthrie, Ph.D.
Shannon McDonough, M.S.

Scientific Leadership
Gastroesophageal: Syma Iqbal, M.D.
Scott A. Hundahl, M.D.
(Though not specifically stated, it is implied that he is a "Surgical representative".)
Pancreatic: Philip A. Philip, M.D., Ph.D.
Andrew M. Lowy, M.D.
(Though not specifically stated, it is implied that he is a "Surgical representative".)
Hepatobiliary: Anthony B. El-Khoueiry, M.D.
Milind Javle, M.D.
Syed Ahmad, M.D.
(Though not specifically stated, it is implied that he is a "Surgical representative".)
Colon: Philip J. Gold, M.D.
Wells A. Messersmith, M.D.
Kevin G. Billingsley, M.D.
(Though not specifically stated, it is implied that he is a "Surgical representative".)
Rectal: Lisa A. Kachnic, M.D.
Cathy Eng, M.D.
Translational Medicine: Heinz-Josef Lenz, M.D.
Christopher H. Lieu, M.D.
Drug Development: Ramesh Ramanathan, M.D.
Sunil Sharma, M.D.
Imaging: Anthony F. Shields, M.D., Ph.D.
David Shin-Kuo Lu, M.D.
Radiation Oncology: Lisa A. Kachnic, M.D.

Designates
Cancer Control Liaison: Jason A. Zell, D.O.
Data Coordinators: Kara Amber
Christine McLeod
Jacqueline Scurlock
Brian Zeller
Oncology Research Professionals:
CRA: Sandy Annis, C.C.R.P.
Nurses: Rita Kaul, R.N., B.S.N.
Valerie A. Parks, R.N.
Patient Advocates: Carole Seigel (pancreatic) and Florence Kurttila (colon)
Pharmaceutical Science: Craig Elg, Pharm.D.
Linda Lee-Gabel, Pharm.D.
Protocol Coordinator: Kimberly F. Kaberle

Agenda • Friday, September 16, 2016 • Room: Regency B • 4:30 p.m. – 6:30 p.m
Introduction: Howard Hochster, M.D., Yale University.

“Treatment Resistance to Anti-EGFR therapy and ctDNA”. Scott Kopetz, M.D., Ph.D., MD Anderson Cancer Center.

Presentation of S1417.
“Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer.” Veena Shankaran, M.D., Fred Hutchinson Cancer Research Center.

Gastroesophageal
Active Studies
CTSU/A021302, “Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study” Dr. Iqbal. Activated: 4/1/16

Pancreatic
Active Studies

S1505, “A Randomized Phase II Study of Perioperative mFOLFIROX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma.” Dr. Sohal. Activated: 10/12/15.
**Hepatobiliary Colon**

**Active Studies**

**S0820.** “A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0–III Colon Cancer, Phase III.” Dr. Zell. Activated: 3/1/13.

**S1417CD.** “Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer.” Dr. Shankaran. Activated: 4/15/16.

**CTSU/E7208.** “A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.” Dr. Hochster. Activated: 1/15/16.

**CTSU/RTOG-1201.** “A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Cancer.” Dr. Murphy. Activated: 3/1/15.

**Rectal**

**Active Studies**


**Other**

**Active Studies**

**S1013.** “A Phase II Prospective Study of Epidermal Growth Factor Receptor (Her01/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy – EGFR 18 (FACT-EGFR18) Questionnaire for EGFR-Induced Skin Toxicities.” Drs. Wong, Moinpour, and Wade. Activated: 11/15/11.


**CTSU/AO21202.** “Prospective Randomized Phase II Trial of Pazopanib versus Placebo in Patients with Progressive Carcinoid Tumors.” Dr. Phan. Activated: 1/15/14.

**CTSU/A021501.** “Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas.” Dr. Ahmad.

**CTSU/E2211.** “A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors.” Dr. Wolin. Activated: 3/1/12.

**CTSU/RTOG 0848.** “A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.” Dr. Philip. Activated: 12/15/09.

**Proposed Studies**

**S1513.** “Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas.” Dr. Ahmad. Activated: 3/1/12.


**S9008A.** “Trial of Adjuvant Chemoradiation after Gastric Resection Adenocarcinoma, Phase III”. Dr. Shridhar.

**S-C80405-A.** “Analysis of EGFR and ERCC1 Markers and Progression-Free Survival in Patients with Advanced Colorectal Cancer Enrolled on C80405”. Drs. Shields and Lenz.

**Other Proposed Studies**

A Two-part Phase II Randomized Study of First and Second Line Therapy in HER2 Positive Metastatic/Locally Advanced (in-operable) Gastric Cancer. Dr. Barzi.

A Randomized Phase II/III Study of Gemcitabine and Cisplatin followed by Capecitabine/Radiation versus Gemcitabine and Cisplatin Alone. Dr. El-Khoueiry.
Genitourinary Committee

Committee Leadership
Chair: Ian M. Thompson, Jr., M.D.
Vice-Chair: Nicholas J. Vogelzang, M.D.
Executive Officer: Christopher W. Ryan, M.D.
Statisticians: Cathy M. Tangen, Dr.P.H.; Melissa Plets, M.S.

Scientific Leadership
Translational Medicine: David J. McConkey, Ph.D.
Radiation Oncology: David Raben, M.D.
Surgery: Daniel J. Culkin, M.D.
Imaging: Daniel W. Lin, M.D.; John D. Hazle, Ph.D.

Medical Oncology: Celestia S. Higano, M.D.
Pathology: M. Scott Lucia, M.D.
Liaison to the SPORES: Colin P.N. Dinney, M.D.
Early Therapeutics: Neeraj Agarwal, M.D.

Designates
Cancer Control: Peter J. Van Veldhuizen, Jr., M.D.
Data Coordinators: Jean Barce; Diana Heaney; Sean O'Bryan

Oncology Research Professionals:
CRA: Debra W. Christie, M.B.A.
Nurse: Deborah A. Halk, R.N.
Patient Advocates: Rick Bangs (bladder); Tony Crispino (prostate)
Pharmaceutical Science:
Jorge G. Avila, Pharm.D.; Jesse Modlin, Pharm.D.
Protocol Coordinator: Nicki Trevino

Active Studies


Renal Cell
Organ Site Chairs: Drs. Primo N. Lara, Jr. (Advanced) and Edward M. Messing (Local)

Active Studies

S1500. “A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozaatinib [NCS #761968], Crizotinib [NCS #749005], Savolitinib [NCS #785348], and Sunitinib [NCS #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET).” Drs. Pal, Lara, and Shuch. Activated: 4/5/16.

Agenda • Saturday, September 17, 2016 • Room: Regency A • 9:30 a.m. – 12:30 p.m.
Introductions and Announcements
Ian Thompson, Jr. M.D.
Translational Medicine in the GU Committee
David McConkey, Ph.D. and Christopher W. Ryan, M.D.
Cancer Control Liaison
Peter J. Van Veldhuizen, M.D.

**Prostate**

Organ Site Chairs: Drs. David I. Quinn (Advanced) and Daniel W. Lin (Local)

**Active Studies**


**Closed Studies**


CTSU/A031201, “A Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer.” Dr. Amir Goldkorn. Activated: 2/1/14; Closed 8/31/16.

**Bladder**

Organ Site Chairs: Drs. Daniel P. Petrylak (Advanced) and Seth P. Lerner (Local)

**Proposed Studies**


**Active Studies**


**Closed Studies**

Committee Leadership

Chair: Harry P. Erba, M.D., Ph.D.
Vice-Chair: Steven E. Coutre, M.D.
Executive Officer: Susan M. O’Brien, M.D.
Statisticians: Megan Othus, Ph.D.
Anna Moseley, M.S.

Scientific Leadership

Translational Medicine: Jerald P. Radich, M.D.
Pathology: David R. Head, M.D.
Cytogenetics Liaison: Diane Roulston, Ph.D.
Min Fang, M.D., Ph.D.

Designates

Data Coordinators: Louise Highleyman, Laura Kingsbury, M.R.T.
Tracy Maher, C.C.R.P.

Oncology Research Professionals:
CRA: TBD

Nurses: Keisha C. Humphries, R.N., B.S.N.
Mary Lynn Rush, R.N., B.S.N.

Patient Advocate: Gail Sperling, M.P.H.

Pharmaceutical Science: Holly O. Chan, Pharm.D.
Joyce Lee, Pharm.D.

Protocol Coordinator: Sandi Hita

Presentation

S1203, “A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA + V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)”

AML/MDS Studies

Active Studies

CTSU/E2905, “Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimg®) Alone and in Combination with Epoetin Alpha (Procrit®) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia.” Dr. C.A. Schiffer. Activated by ECOG: 1/29/09; Activated by SWOG: 2/15/09.

Closed Studies


Proposed Studies

S1612, “A Randomized Phase II/III Trials of “Novel Therapeutic Regimens” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia Age 60 or Older” Drs. L. Michaelis and R. Walter.

Leukemia Committee Updates – Dr. Harry Erba

Agenda • Saturday, September 17, 2016 • Regency C • 9:30-11:30 a.m.
ALL Studies

Active Studies

S1318, "A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL." Drs. A.S. Advani and K. O'Dwyer. Activated 1/12/2015.

S1312, "A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia)." Drs. A.S. Advani and M. Liedtke. Activated 4/1/14.


Closed Studies


Proposed Studies

SXXXX, "A Phase II Trial of PR-104 in Relapsed/Refractory Patients with T-cell Acute Lymphoblastic Leukemia" Drs. A.S. Advani and W. Stock.

A041501, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a conjugated anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 16-39 years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A.S. Advani.

CML Studies

Proposed Studies

S1615, "A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease" Dr. K. Sweet.
Committee Leadership
Chair: Karen Kelly, M.D.
Vice-Chair: Stephen G. Swisher, M.D.
Executive Officer: Julie R. Gralow, M.D.
Statisticians: Mary Redman, Ph.D. Jieling Miao, M.S. James Moon, M.S. Kathrine Griffin, M.S. (Lung-MAP Protocol)

Scientific Leadership
Translational Medicine: Philip C. Mack, Ph.D. Fred R. Hirsch, M.D., Ph.D.
Radiation Oncology: Laurie E. Gaspar, M.D. Roy Decker, M.D.
Surgery: Stephen G. Swisher, M.D.
Imaging: Anthony F. Shields, M.D., Ph.D. Friedrich D. Knollmann, M.D., Ph.D.
Medical Oncology: Karen Kelly, M.D.
Pathology: Ignacio I. Wistuba, M.D.

Developmental Therapeutics: Roy S. Herbst, M.D., Ph.D.
Early Therapeutics: Shirish M. Gadgeel, M.D.

Designates
Cancer Control Liaison: Gary E. Goodman, M.D.
Community Affiliate: Paul J. Hesketh, M.D.
Data Coordinators: Kara Amber Louise Highleyman Larry Kaye Sarah Basse, SDMC Project Manager (Lung-MAP Protocol)

Oncology Research Professionals:
CRAs: Courtney L. Williamson Ginny M. Keeling, M.S.
Nurses: Kimberly M. Belzer, M.S., P.A.C Rosalie Zablocki, R.N.
Patient Advocate: Judy Johnson, M.B.A.
Pharmaceutical Science: Joyce Lee, Pharm.D. Daniel L. Hertz, Pharm.D.

Agenda • Friday, September 16, 2016 • Crystal B • 4:00 p.m. – 7:00 p.m.

4:00 P.M.
Opening Remarks
Dr. Kelly
General Update

4:05 P.M.
Thoracic Surgery Session – Dr. Swisher
• Update on Current Trials
• Review of Trials in Development

4:20 P.M.
Thoracic Radiation Session – Dr. Gaspar and Dr. Decker
• Update on Current Trials
• Review of Trials in Development

4:45 P.M.
Translational Medicine Session
Dr. Hirsh & Dr. Mack
• Update
• Presentation “Blue Print Comparison Project” Fred Hirsh, MD, PhD

5:15 P.M.
Thoracic Oncology Session
• Guest Presentation “Mechanisms of Immunotherapy Resistance” Thomas Gajewski, MD, PhD, University of Chicago Medicine

5:45 P.M.
Translational Medicine Session
Dr. Hirsh & Dr. Mack
• Update
• Presentation “Blue Print Comparison Project” Fred Hirsh, MD, PhD

6:00 P.M.
NSCLC
• Update on Current Trials
• Review of Trials in Development

6:45 P.M.
Small Cell Lung Cancer
• Update on Current Trials
• Review of Trials in Development

Mesothelioma
• Update on Current Trials
• Review of Trials in Development

Thymoma
• Review of Trial in Development
**Active Studies**

**S1507.** “A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies.” Drs. Gadgeel, Riess and Mack. **Activated 7/17/16**

**S1403.** “A Randomized Phase II/III Trial of Afatinib Plus Cetuximab versus Afatinib Alone in Treat-ment-Naïve Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC).” Drs. Goldberg, Lilenbaum and Politi. **Activated: 3/25/15.**


**S1400B.** “A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer. (Lung-MAP Sub-study)” Drs. Langer and Wade. **Activated: 8/1/14; Temporarily closed: 9/2/15.**

**S1400C.** “A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer. (Lung-MAP Sub-study)” Drs. Edelman and Albain. **Activated: 6/16/14.**

**S1400D.** “A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer. (Lung-MAP Sub-study)” Drs. Aggarwal and Lara. **Activated: 6/16/14.**

**S1400I.** “A Phase III Randomized Study of Nivolumab plus Iplimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-study).” Drs. Getttinger and Bazhenova. **Activated: 12/18/15.**

**S1300.** “A Randomized Phase II Trial of Crizotinib plus Pemetrexed versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients who have Progressed Systemically after Previous Clinical Benefit from Crizotinib Monotherapy.” Drs. Camidge, Li and Doebele. **Activated: 8/1/14; Temporarily closed: 9/2/15.**


**S1013.** “A Prospective Study of Epidermal Growth Factor Receptor (Her-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFR-induced Skin Toxicities.” Drs. Wong and Wade. **Activated: 11/15/11.**

**CTSU/A081105.** “Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC).” Dr. Kelly. **Activated: 8/18/14.**

**CTSU/E4512.** “A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lympho-ma Kinase (ALK) Fusion Protein.” Dr. Li. **Activated: 8/18/14.**

**CTSU/R1306.** “A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer.” Drs. Tsao and Daly. **Activated: 11/4/13.**

**CTSU/CALGB 30610.** “Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide.” Drs. Gadgeel and Gaspar. **Activated: 3/15/08.**


**CTSU/A151216.** “Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (AL-CHEMIST).” Dr. Gandara. **Activated: 8/18/14.**

**CONTINUED NEXT PAGE**
Lung Committee

Proposed Studies

S1619. “A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Resectable Malignant Pleural Mesothelioma.” Dr. Tsao.

S1400G. “A Phase II Randomized Study of Talazoparib for Previously-Treated Homologous Recombination Repair Deficiency Positive Patients with Squamous Cell Lung Cancer (Lung-MAP Sub-study).” Drs. Owonikoko and Byers.

S1400F. A Phase II Study of MEDI4736 Plus Tremelimumab as Therapy for Previously Treated Checkpoint Inhibitor Refractory Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study) Drs. Leigl and Rizvi.

ECOG/SWOG. “A Randomized Phase III Study for PD-L1 Positive Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Pembrolizumab in Induction or Maintenance Therapy with Immunosignature-Driven Analysis.” Dr. Chiang.

“A Phase II Study of PARP inhibitor (Niraparib) and PD-1 inhibitor (Pembrolizumab) in Patients with Homologous Recombinant Repair (HRR) deficient NSCLC who have Progressed after Initial Platinum-based Therapy.” Dr. Ramnath and Dr. Warren.

“Randomized Phase II Trial to Test the Efficacy of BIBF1120 in Combination with Cisplatin and Etoposide for Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer.” Dr. Heymach.

“A Phase II Trial of Carboplatin, Paclitaxel, and Ramucirumab in Patients with Locally Advanced, Metastatic, or Recurrent Thymic Epithelial Tumors (TET) not Amenable to Curative Intent Surgery.” Dr. Tsao.


Closed Studies

S1400A. “A Phase II Study of MEDI4736 for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers.” Drs. Papadimitrakopoulou and Borghaei. Activated: 6/16/14, Closed 12/18/15.


Do you have a few minutes between meetings?

Stop by the SWOG registration desk in the Regency Foyer (Gold Level, West Tower) to check your e-mail and/or print your boarding pass!
Lymphoma Committee

**Committee Leadership**
- **Chair:** Jonathan W. Friedberg, M.D.
- **Vice-Chair:** Sonali M. Smith, M.D.
- **Executive Officer:** Susan M. O’Brien, M.D.
- **Statisticians:** Michael LeBlanc, Ph.D. Hongli Li, M.S.

**Scientific Leadership**
- **Translational Medicine:**
  - Owen A. O’Connor, M.D., Ph.D.
- **Radiation Oncology:**
  - Louis S. Constine, M.D.
- **Imaging:**
  - Oliver W. Press, M.D., Ph.D.
  - Lawrence H. Schwartz, M.D.
- **Pathology:**
  - Lisa M. Rimsza, M.D.
  - Early Therapeutics:
    - Daruka Mahadevan, M.D., Ph.D.

**Designates**
- **Cancer Control:** TBD
- **Data Coordinators:**
  - Jeri Jardine
  - Iris Syquia
- **Oncology Research Professionals:**
  - CRA: Erin M. Cebula, M.P.H.

**Nurse:** TBD
**Patient Advocate:** Hildy Dillon, M.P.H.
**Pharmaceutical Science:**
- Lara M. Au, Pharm.D.
- Holly O. Chan, Pharm.D.
**Protocol Coordinator:** Megan Hardin

---

**Agenda • Friday, September 16, 2016 • Regency A • 4:00 – 7:00 p.m.**

1. **Report of Ongoing Studies:**
   - Drs. Amengual, Till, Stiff and Fanale

2. **Upcoming Trials**
   - **a. Follicular lymphoma:** Dr. Barr
   - **b. Mantle cell lymphoma:** Dr. Till

3. **ASH abstract preview**
   - **a. S0801:** Dr. Barr
   - **b. S0016 long-term follow-up:** Dr. Shadman
   - **c. S9704 T-cell subset:** Dr. Stiff

4. **Monitoring patients with lymphoma after treatment:**
   - update: Dr. Phillips and Dr. S. Smith

5. **Correlative Science**
   - **Update:** S0016 Genomic Alterations Analysis: Dr. Fang

6. **Guest Speaker:**
   - Dr. Brian Link, Professor of Medicine, University of Iowa:
     - Accomplishments of lymphoma registries, and how registries can collaborate with NCTN and SWOG.

**Non-Hodgkin Lymphoma**

**S1001**, “A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL).” Drs. Persky, Constine, Rimsza, and Fitzgerald. **Activated:** 7/18/11.

**CTSU/E1411**, “Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Un-treated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab +Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV → R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR).” Dr. Till. **Activated:** 5/22/12.

**CTSU/E1412**, “Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCO (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma.” Dr. Amengual. **Activated:** 6/1/14.

**CTSU/9177**, “Phase II Study of Dose-Adjusted EPOCH +/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma.” Dr. Fanale. **Activated:** 4/13/12.

**CTSU/CALGB S1101**, “A Randomized Phase II Trial of Myeloablative versus Non-Myeloablative Con-solidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma.” Dr. Mohile. **Activated:** 6/15/12.

**EAY 131**, “Molecular Analysis for Therapy Choice (MATCH),” **Activated:** 8/12/15.

**CTSU/A051301**, “A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype.” Dr. Stiff. **Activated:** 7/6/16.

**Cancer Control Studies**

**S1204**, “A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) and Hepatitis C virus (HCV) Among Newly Diagnosed Cancer Patients.” Drs. Ramsey, Loomba, Chugh, Hershman and Huang. **Activated:** 8/29/13.

**Studies in Development**

**S1608**, “Randomized Phase II Trial in High-Risk Relapsed Refractory Follicular Lymphoma.” Dr. Barr
Melanoma Committee

Committee Leadership
Chair: Antoni Ribas, M.D., Ph.D.
Vice-Chair: William E. Carson, Ill, M.D.
Executive Officer: Christopher W. Ryan, M.D.
Statisticians: Megan Othus, Ph.D.
James Moon, M.S.
Michael Wu, Ph.D.

Scientific Leadership
Translational Medicine: William E. Carson, Ill, M.D.
Radiation Oncology: Evan J. Wuthrick, M.D.
Surgery: Robert H.I. Andtbacka, M.D.
Imaging: Kenneth F. Grossman, M.D., Ph.D.
Martin Allen-Auerbach, M.D.
Medical Oncology: Lawrence E. Flaherty, M.D.
Pathology: TBD

Non-Melanoma Skin Cancer: Sancy A. Leachman, M.D., Ph.D.

Early Therapeutics:
Jeffrey A. Sosman, M.D.
ECOG-ACRIN Liaison
Kenneth F. Grossman, M.D., Ph.D.

Designates
Cancer Control Liaison: Sancy Leachman, M.D., Ph.D.

Data Coordinator: Jennie Barrett
ECOG Liaison: Kenneth F. Grossman, M.D., Ph.D.

Oncology Research Professionals:
CRAs: Kacie L. Simpson, B.S., C.C.R.P.
Nurses: Karen L. Mack, R.N.P.
Ann M. Lau Clarke, R.N., M.S.N.
Lisa S. Morgan, R.N., O.C.N.
Patient Advocate: Valerie Guild, M.B.A., C.P.A.
Pharmaceutical Science: Linda Lee-Gabel, Pharm.D.
Protocol Coordinator: Kimberly F. Kaberle

Agenda • Friday, September 16, 2016 • Crystal B • 9:30 – 11:30 a.m.

9:30-10:15 AM:
Scientific Presentation
Ashani Weeraratna, PhD, Wistar Institute, Philadelphia, PA

10:15-10:30 AM:
Panel discussion

10:30-11:30 AM:
SWOG Melanoma Committee Clinical Trials

Active Studies

S1320, “A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma” Drs. Algazi, Daud, and Lo. Activated: 7/22/14.

S1404, “A Phase III Randomized Trial Comparing High-Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High-Risk Resected Melanoma.” Drs. Grossmann and Patel.

CTSU/EA6134, “A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Pro-gression in Patients with Advanced BRAFV600 Mutant Melanoma”. Dr. Chmielowski. Activated: 9/1/15.

CTSU/EA6141, “Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma.” Dr. Kim. Activated 8/1/16.

Upcoming Studies
S1512, “A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM).” Drs. Kendra and Hu-Lieskovkan.

S1603, “A Phase II Study of PD-1 Blockade with Pembrolizumab in Patients with Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin.” Drs. Cowey and Hu-Lieskovkan.

S1607, “A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy.” Dr. Hu-Lieskovkan.

S1616, “Combining Ipilimumab and Nivolumab in Advanced Melanoma Following Progression on a PD-1 Inhibitor Alone.” Dr. VanderWalde.
The publications listed below were received by the group chair’s office as published, accepted, and submitted or reflect change in publication status since the SWOG Fall 2015 SWOG Group Meeting. Not included are submitted or accepted publications where posting is not permitted due to journal embargo policy (e.g., NEJM). Conference abstracts are also not included.

ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

Published/Accepted Manuscripts

Study N/A


Submitted Manuscripts

S0777


BARLOGIE-SALMON MYELOMA COMMITTEE

Published/Accepted Manuscripts

S0120


S0800


S09630


MA.17 & 17R

Extending aromatase-inhibitor adjuvant therapy to 10 years. PE Goss, JN Ingle, KJ Pritchard, NJ Robert

NCIC CTG

Publication List by Committee

Submitted Manuscripts

S0221 Supplement use and chemotherapy-induced peripheral neuropathy in patients treated in a SWOG cooperative group trial (S0221): the DELCaP Study. G Zirpoli, S McCann, L Sucheston-Campbell, D Hershman, G Ciupak, W Davis, J Unger, H Moore, JA Stewart, C Isaacs, T Hobday, M Salim, R Livingston, G Hortobagyi, J Gralow, D Moore, H Campbell, D Hershman, G S McCann, L Sucheston-The DELCaP Study. G Zirpoli, cooperative group trial (S0221): patients treated in a SWOG

Multiple Studies


Multiple Studies


Multiple Studies


Multiple Studies


Submitted Manuscripts

(none this cycle)

Cancer Survivorship Committee

Published/Accepted Manuscripts


CONTINUED NEXT PAGE

**S0000/S9217**


**S0000/other**


**S0000/other**

Publication List by Committee


**S9217**


**S9217**


**S9217**


**S9630**

**N/A**


Submitted Manuscripts

**S0000**


**S0000D**

**S9217**
A pooled analysis of 15 prospective cohort studies on the association between fruit, vegetable, and mature bean consumption and risk of prostate cancer. J Petimar, KM Wilson, K Wu, D Albanes, PA van den Brandt, MB Cook, GG Giles, E Giovannucci, GG Goodman, PJ Goodman, N Håkansson, K Helzlsouer, LN Kolonel, LM Liao, S Männistö, ML McCullough, R Milne, ML Neuhausen, Y Park, EA Platz, N Sawada, JM Schen, T Tsugane, B Verhage, M Wang, Y Wang, LR Wilkens, A Wolk, RG Ziegler,
Publication List by Committee

SA Smith-Warner, American Journal of Epidemiology, submitted 8/12/16.

**S9630/Multiple Studies**
How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? KD Crew, KS Albin, DL Hershman, JM Unger, SS Lo. NPI Breast Cancer, pending resubmission. [commentary]

**Symptom Control and Quality of Life Committee**

**Published/Accepted Manuscripts**

**S9208/S9133**

**Submitted Manuscripts**

**S0221**
Supplement use and chemotherapy-induced peripheral neuropathy in patients treated in a SWOG cooperative group trial (S0221): the DELCaP Study. G Zirpoli, S McCann, L Sucheston-Campbell, D Hershman, G Ciupak, W Davis, J Unger, H Moore, JA Stewart, C Isaacs, T Hobday, M Salim, R Livingston, G Hortobagyi, J Gralow, D Hayes, G Budd, K Albain, C Ambrosone. Journal of Clinical Oncology, under review. [see also Breast Committee]

**S0702**
Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702. CH Van Poznak, A Darke, CM Moinpour, RA: Bagramian, MM Schubert, JR Gralow, JL Wade, III, JM Unger. Supportive Care in Cancer, submitted 7/29/16.

**EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE**

**Published/Accepted Manuscripts**

(none this cycle)

**Submitted Manuscripts**

**S8892/Multiple Studies**

**S8892/Multiple Studies**

**E4397**

**GASTROINTESTINAL COMMITTEE**

**Published/Accepted Manuscripts**

**S9415/Multiple Studies**

**A021101**

**N0147**
Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147. A Phipps, Q Shi, P Limburg, GD Nelson, DJ Sargent, FA Sinicrope, E Chan, S Gill, RM Goldberg, M Kahlenberg, S Nair, AF Shields,
Publication List by Committee


[see also Cancer Survivorship]

Submitted Manuscripts

**S0033**


**S0518**


**S0713**


**S1115**


GENITOURINARY COMMITTEE

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

Published/Accepted Manuscripts

**S8710/other**


**Multiple**


LEUKEMIA COMMITTEE

Published/Accepted Manuscripts

**S0106**


**E1908**


CONTINUED NEXT PAGE

**Multiple**

**Multiple Studies**
Prediction of CR following a second course of “3+7” in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. M Othus, S Mukherjee, MA Sekeres, J Godwin, S Petersdorf, F Appelbaum, H Erba, F Appelbaum, H Erba, A List. *includes other groups/institutions, as well as SWOG studies S0106, S0703, S9031, S9333.


**Submitted Manuscripts**

**S0635**

**S0636**

**LUNG COMMITTEE**

**Published/Accepted Manuscripts**

**S0816**

**S0816**


**S0816**

**S9704**
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell
transplant:

**CONTINUED NEXT PAGE**


**BMT/CTN 0701**


**Submitted Manuscripts**

**S0016/Other**


**S0816**


**S1106**


**Multiple Studies*/Other**


**N/A**


**N/A**


**MELANOMA COMMITTEE**

**Published/Accepted Manuscripts**

**Multiple Studies*/Other**


*studies S0008, S9430, S1404.


**Submitted Manuscripts**

(none this cycle)
Special thanks to our 2016 Group Meeting Commercial Supporters*

We value their partnership.

CME

Platinum Supporters
Celgene

Silver Supporters
AstraZeneca
Merck

Gold Supporters
AbbVie
Amgen
Eli Lilly & Co.
Novartis

Bronze Supporters
Genomic Health

Non-CME

Platinum Supporters
Takeda Oncology

Exhibitors
Novartis Oncology
AstraZeneca
Seattle Genetics
Gilead Sciences
DDOTS
Cancer Trials Support Unit (CTSU)
Jazz Pharmaceuticals

*Supporters as of August 4, 2016
Notes